Doping-Control Analysis of the 5α-Reductase Inhibitor Finasteride: Determination of Its Influence on Urinary Steroid Profiles and Detection of Its Major Urinary Metabolite

April 2007 in “ Therapeutic Drug Monitoring ”

Mario Thevis, Hans Geyer, Ute Mareck, Ulrich Flenker, Wilhelm Schänzer

finasteride 5α-reductase inhibitor urinary steroid profiles steroid metabolism benign prostatic hyperplasia alopecia acne doping control analysis synthetic steroid Propecia BPH hair loss doping control

Studysummary This study found that finasteride significantly alters urinary steroid profiles, complicating the detection of steroid abuse in doping-control analysis by potentially causing false-negative results.

Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer

View this study on journals.lww.com →

Discuss this study in the Community →

Research cited in this study

9 / 9 results

research Medicolegal Aspects of Doping in Football

12 citations , June 2006 in “British Journal of Sports Medicine”

This article reviews the history and current medicolegal challenges of doping in sports, focusing on FIFA's procedures and three urgent legal issues, but presents no new findings.

research Changes in Hair Weight in Men with Androgenetic Alopecia After Treatment with Finasteride (1 mg Daily): Three- and Four-Year Results

66 citations , June 2006 in “Journal of The American Academy of Dermatology”

This study found that long-term finasteride treatment in men with androgenetic alopecia significantly increased hair weight and count compared to placebo over nearly four years.

research Inhibitors of 5α-Reductase in the Treatment of Benign Prostatic Hyperplasia

52 citations , February 2006 in “Current pharmaceutical design”

This review discusses the use of 5α-reductase inhibitors in treating benign prostatic hyperplasia, highlighting their long-term effectiveness and benefits when combined with α1-adrenergic antagonists; it reports no new clinical results.

research Steroidogenic Isoenzymes in Human Hair and Their Potential Role in Androgenetic Alopecia

31 citations , January 2003 in “Dermatology”

This article provides an overview of recent discoveries about steroidogenic enzymes involved in androgenetic alopecia but reports no new clinical results.

research Male Androgenetic Alopecia

54 citations , July 2002 in “Clinical and Experimental Dermatology”

This article provides a critical overview of recent discoveries in the genetics and molecular processes involved in androgenetic alopecia, focusing on its polygenic basis and DHT dependency, but reports no new clinical results.

research Separation of Finasteride and Analogues

11 citations , November 2001 in “Journal of Chromatography B: Biomedical Sciences and Applications”

This review discusses various chromatographic methods for analyzing finasteride in biological fluids and provides no clinical findings, focusing on detection techniques for different concentration levels.

research Clinical Application of 5α-Reductase Inhibitors

46 citations , March 2001 in “Journal of endocrinological investigation”

This review discusses the use of 5α-reductase inhibitors, particularly finasteride, for treating conditions like benign prostatic hyperplasia, male baldness, and hirsutism, and reports no new clinical results.

research Finasteride

40 citations , April 1999 in “Drugs”

This study concluded that finasteride is a viable first-line treatment for moderate uncomplicated benign prostatic hyperplasia, particularly in patients with larger prostates, by significantly reducing acute urinary retention and the need for surgery.

research Finasteride, a Type 2 5α-Reductase Inhibitor, in the Treatment of Men with Androgenetic Alopecia

32 citations , April 1999 in “Expert Opinion on Investigational Drugs”

Clinical studies reported that finasteride reduces scalp dihydrotestosterone levels and improves hair growth in men with androgenetic alopecia, supporting its role as a treatment option.